122 related articles for article (PubMed ID: 37732197)
1. A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
Verma R; da Silva KE; Rockwood N; Wasmann RE; Yende N; Song T; Kim E; Denti P; Wilkinson RJ; Andrews JR
medRxiv; 2023 Sep; ():. PubMed ID: 37732197
[TBL] [Abstract][Full Text] [Related]
2. A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
Verma R; da Silva KE; Rockwood N; Wasmann RE; Yende N; Song T; Kim E; Denti P; Wilkinson RJ; Andrews JR
Am J Respir Crit Care Med; 2024 Jun; 209(12):1486-1496. PubMed ID: 38647526
[No Abstract] [Full Text] [Related]
3. A Rapid Pharmacogenomic Assay to Detect
Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
[No Abstract] [Full Text] [Related]
4. A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing.
Gliddon HD; Frampton D; Munsamy V; Heaney J; Pataillot-Meakin T; Nastouli E; Pym AS; Steyn AJC; Pillay D; McKendry RA
Microbiol Spectr; 2021 Dec; 9(3):e0061021. PubMed ID: 34817282
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
[TBL] [Abstract][Full Text] [Related]
6. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Ulanova V; Kivrane A; Viksna A; Pahirko L; Freimane L; Sadovska D; Ozere I; Cirule A; Sevostjanovs E; Grinberga S; Bandere D; Ranka R
Front Pharmacol; 2024; 15():1332752. PubMed ID: 38584604
[No Abstract] [Full Text] [Related]
7. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
8.
Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
[TBL] [Abstract][Full Text] [Related]
9. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
10. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
[TBL] [Abstract][Full Text] [Related]
11. Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study.
Gao Y; Davies Forsman L; Ren W; Zheng X; Bao Z; Hu Y; Bruchfeld J; Alffenaar JW
Br J Clin Pharmacol; 2021 Mar; 87(3):1347-1358. PubMed ID: 33464624
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
Rens NE; Uyl-de Groot CA; Goldhaber-Fiebert JD; Croda J; Andrews JR
Clin Infect Dis; 2020 Dec; 71(12):3136-3143. PubMed ID: 31905381
[TBL] [Abstract][Full Text] [Related]
14. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients.
Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
Sci Rep; 2023 Jul; 13(1):11438. PubMed ID: 37454203
[TBL] [Abstract][Full Text] [Related]
15. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
16. Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.
Wu SH; Xiao YX; Hsiao HC; Jou R
Microbiol Spectr; 2022 Dec; 10(6):e0260522. PubMed ID: 36255328
[TBL] [Abstract][Full Text] [Related]
17. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis.
Hemanth Kumar AK; Ramesh K; Kannan T; Sudha V; Haribabu H; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2017 Jan; 145(1):118-123. PubMed ID: 28574024
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
20. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Thomas L; Raju AP; Chaithra ; M SS; Varma M; Saravu K; Banerjee M; Sv CS; Mallayasamy S; Rao M
Eur J Clin Pharmacol; 2022 Oct; 78(10):1535-1553. PubMed ID: 35852584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
